Leber Congenital Amaurosis Clinical Trial
Official title:
Safety and Efficacy of LX101(AAV2-RPE65) in Patients With Leber's Congenital Amaurosis: a Randomised, Controlled, Open-label, Trial
The purpose of this study is to determine whether gene transfer(LX101) will be safe and effective in the treatment of Leber Congenital Amaurosis (LCA).
Status | Not yet recruiting |
Enrollment | 9 |
Est. completion date | June 1, 2023 |
Est. primary completion date | December 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 80 Years |
Eligibility | Inclusion Criteria: Age 4 years old or older at the time of administration; Diagnosed with LCA; Molecular diagnosis of LCA due to RPE65 mutations (homozygotes or compound heterozygotes) by a qualified laboratory; Visual acuity = 20/200 or visual field less than 20 degrees in the eye to be injected; Must be willing to adhere to protocol and companion protocol for long-term follow-up as evidenced by written informed consent or parental permission and subject assent. Exclusion Criteria: Unable or unwilling to meet requirements of the study; Participation in a clinical study with an investigational drug in the past six months; Pre-existing eye conditions that would preclude the planned surgery or interfere with the interpretation of study endpoints (for example, glaucoma, corneal or lenticular opacities); Lack of sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy. Specifically, if indirect ophthalmoscopy reveals less than 1 disc area of retina which is not involved by complete retinal degeneration (indicated by geographic atrophy, thinning with tapetal sheen, or confluent intraretinal pigment migration), these eyes will be excluded. In addition, in eyes where optical coherence tomography (OCT) scans of sufficient quality can be obtained, areas of retina with thickness measurements less than 100 um, or absence of neural retina, will not be targeted for delivery of LX101(AAV2-RPE65); Complicating systemic diseases or clinically significant abnormal baseline laboratory values. Prior ocular surgery within six months. Known sensitivity to medications planned for use in the peri-operative period. Individuals of childbearing potential who are pregnant or unwilling to use effective contraception for the duration of the study. Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study and, in the opinion of the investigator, makes the potential subject unsuitable for the study. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai General Hospital | Shanghai | Shanghai |
China | Shanghai General Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Full-field light sensitivity threshold (FST) | The primary efficacy endpoint, designed to measure the effect of intervention on functional vision, was the change in FST testing.FST measures the lowest illumination perceived-light sensitivity-over the entire visual field, is therefore unaffected by nystagmus, and is useful over a wide range of visual impairment. FST test-retest variability has been stated as 0·3 log and a meaningful change has been suggested as 10 dB or 1 log. | 30, 90, 180, and 365 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01496040 -
Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65
|
Phase 1/Phase 2 | |
Completed |
NCT02970266 -
Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families.
|
N/A | |
Completed |
NCT00516477 -
Safety Study in Subjects With Leber Congenital Amaurosis
|
Phase 1 | |
Active, not recruiting |
NCT03920007 -
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
|
Phase 1/Phase 2 | |
Recruiting |
NCT05906953 -
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00999609 -
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
|
Phase 3 | |
Active, not recruiting |
NCT01208389 -
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
|
Phase 1/Phase 2 | |
Terminated |
NCT03913130 -
Extension Study to Study PQ-110-001 (NCT03140969)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04855045 -
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
|
Phase 2/Phase 3 | |
Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
Completed |
NCT00749957 -
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Recruiting |
NCT05203939 -
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT06064565 -
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial (LIGHT)
|
Early Phase 1 | |
Recruiting |
NCT06088992 -
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)
|
Early Phase 1 | |
Completed |
NCT00821340 -
Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
|
Phase 1 | |
Active, not recruiting |
NCT03913143 -
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
|
Phase 2/Phase 3 | |
Completed |
NCT02781480 -
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
|
Phase 1/Phase 2 | |
Completed |
NCT02714816 -
Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
|